Generic biotech drugs likely to be on the market in the next decade, Dillon Read's Treppel predicts.
GENERIC BIOTECH DRUGS LIKELY TO BE ON MARKET IN NEXT DECADE, DILLON READ analyst Jerry Treppel predicted at his firm's generic drug/delivery systems financial conference May 7 in New York City. The next wave of new ANDAs in the first decade of the 21st century will be for products coming off patent at the beginning of the decade such as EPO, tPA, IL-2 and growth factors, Treppel said in his overview of the industry. He added that bioequivalence will not be an issue with injectable generic biotech drugs; "patents, particularly process patents, will be."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth